Nxera Pharma Co Ltd SOLTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 91.38M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 322
- Website
- https://www.nxera.life
Valuation
|
Metric
|
SOLTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.78 |
Price/Sales | 3.59 |
Price/Cash Flow | 26.40 |
Price/Earnings
SOLTF
Financial Strength
|
Metric
|
SOLTF
|
|---|---|
Quick Ratio | 1.88 |
Current Ratio | 2.66 |
Interest Coverage | −0.55 |
Quick Ratio
SOLTF
Profitability
|
Metric
|
SOLTF
|
|---|---|
Return on Assets (Normalized) | −4.63% |
Return on Equity (Normalized) | −9.94% |
Return on Invested Capital (Normalized) | −1.21% |
Return on Assets
SOLTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mH!?G<& | LOCK|kGN#! | $126B | |||
| Moderna Inc
MRNA
| LOCK|>?>Mz$l | LOCK|Cp! | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$B@p%? | LOCK|%&L#f | $80B | |||
| argenx SE ADR
ARGX
| LOCK|rVG>g$ | LOCK|#k$ | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!V&@qh | LOCK|zD | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|R<w<>K? | LOCK|hrQ$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^rv?gR% | LOCK|y%vg^ | $26B | |||
| Incyte Corp
INCY
| LOCK|!C#M<#p | LOCK|%@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|q%#!$j% | LOCK|%YL | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@>CS?^r | LOCK|m< | $14B |
United States